Also, although there is clinical event reduction data at lower doses in diabetics, getting these data at higher doses in obesity will be very important, especially to support insurers paying a substantial part of the cost of this medication. Also important to learn, Neeland said, is that what is not known, and is not able to be known from the STEP program, are whether there are select benefits in patients with excess visceral adiposity as opposed to excess subcutaneous fat where the fat is in the body, is that related to the weight-loss response, and is it, potentially, then related to the CV benefit? Individualized interventions coupled with the right pharmacotherapy are key, though that often involves trial and error, Stanford said
I don't hate that
They can help you determine whether there are other issues to address to treat the problem at its root
Affordable, Simple Weight Loss Injections One of the key advantages of compounded liraglutide is its simple daily dosing regimen
In analyses excluding individuals with no BMI information and using multiple imputation for BMI missing values, respective HRs were 0.89 (95% CI 0.26, 3.14) and 1.29 (95% CI 0.42, 3.92) (Table 2)
Frequently Asked Questions Is it safe to take tirzepatide and phentermine at the same time